Sorrento And Mabpharm Get ‘Biobetter’ Infliximab Approval In China
Plans To File Biosimilar With Improved Safety Profile In US And Europe This Year
Sorrento and Mabpharm have revealed plans to take their infliximab “biobetter” global, after China’s NMPA approved the product, which has an improved safety profile compared to Remicade.
You may also be interested in...
Banking on the burgeoning biosimilars approvals in China, Sorrento’s partner Mabpharm has filed in China for an infliximab biosimilar. Sorrento plans to follow this up with a US filing for a ‘biobetter’ version via the BLA route in 2020.
Celltrion head of clinical development Sang Joon Lee has set out the promise of ‘biobetters’ – biosimilars that improve upon the original reference product – at the FT Global Pharmaceutical and Biotechnology Conference 2019. However, obstacles remain, including the lack of a tailored regulatory pathway.
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.